- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Grants Dapagliflozin Priority Review for Heart Failure, Even for Those Without Diabetes
Priority review was based on phase 3 results from DAPA-HF, presented in Paris at the European Society of Cardiology and published in the New England Journal of Medicine.
The FDA this week granted priority review status to the supplemental new drug application (sNDA) for dapagliflozin to reduce the risk of cardiovascular (CV) death or worsening of heart failure regardless of diabetes status. Dapagliflozin is sold as Farxiga by AstraZeneca.
Priority review status was based on results of the phase 3 DAPA-HF trial, which was presented in Paris at the European Society of Cardiology and published in the New England Journal of Medicine. Those results showed taking the sodium glucose co-transporter 2 (SGLT2) inhibitor reduced the risk of CV death or heart failure hospitalization and urgent care measures by 26%.
Of note, the outcomes were the same for patients with and without type 2 diabetes. Benefits were substantial for at-risk patients without prior hospitalization, who saw a 33% risk reduction, as well as those who were obese, who saw a 31% risk reduction.
“Farxiga is well established in the treatment of type 2 diabetes and this priority review shows its potential to also impact millions of patients with heart failure,” Mene Pangalos, executive vice president for AstraZeneca BioPharmaceuticals Research and Development, said in a statement. “If approved, Farxiga will be the first and only medicine of its kind indicated to treat patients with heart failure.”
The news follows the FDA’s announcement in September that dapagliflozin had received Fast Track designation in heart failure. In August, dapagliflozin received Fast Track designation for the prevention of renal failure and CV and renal death in patients with chronic kidney disease, regardless of diabetes status.
In October, the FDA approved dapagliflozin to reduce the risk of hospitalization for heart failure in patients with T2D and established cardiovascular disease or multiple CV risk factors. This was based on results of DECLARE-TIMI, the cardiovascular outcomes trial required by the FDA of new glycemic-lowering therapies; results were reported in November 2018.
Patients With HFrEF, HFpEF See Different Functional Capacity Benefits With Dapagliflozin
December 7th 2023The DETERMINE-Reduced and DETERMINE-Preserved trials demonstrated varying benefits of dapagliflozin on Kansas City Cardiomyopathy Questionnaire Total Symptom Score and Physical Limitation Scale as well as 6-minute walk distance.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Intermountain Healthcare and Story Health Partner to Optimize Rural Heart Failure Care
February 7th 2023On this episode of Managed Care Cast, we speak with Tom Stanis, CEO and cofounder of Story Health, and Phillip Wood, Intermountain Ventures program director, on how their partnership came about, how it is going so far, and the future of their collaboration.
Listen
Benefits of Excluding Aspirin From Antithrombotic Regimen in Patients With LVADs
November 15th 2023New research highlighted how aspirin is unnecessary in antithrombotic regimens for patients with advanced heart failure and fully magnetically levitated left ventricular assist devices (LVADs).
Read More
